# Han Lee

> Han Lee, Ph.D., is co-CEO of Vibrant Therapeutics, a clinical-stage biotech building logic-gated, conditionally activated antibody prodrugs designed to switch on only inside diseased tissue. A Yale-trained geneticist with an MBA who can read a sequencing run and a term sheet with equal fluency, Lee spent 15 years as the finance and dealmaking engine behind cell-therapy companies - Arcellx, Neogene, and ImmPACT Bio - steering more than 75 transactions worth billions, including two startup exits to AstraZeneca and Lyell Immunopharma. In January 2026 he joined founder Larry Wang to scale Vibrant globally and push its lead masked T-cell engager, VIB305, into the clinic.

- **Role:** Co-CEO at Vibrant Therapeutics
- **Organizations:** Vibrant Therapeutics, ImmPACT Bio, Neogene Therapeutics, Arcellx, AstraZeneca
- **Nationality:** American
- **Education:** Ph.D. in Genetics, Yale University, MBA, Yale University, B.A. in Molecular Cell Biology (genetics emphasis), minor in Chemistry, University of California, Berkeley
- **Known for:** Led or contributed to more than 75 transactions spanning financings, IPO preparations, mergers, acquisitions, and strategic partnerships worth billions in aggregate value., Served as CFO of two cell-therapy startups (Neogene and ImmPACT Bio) that both reached successful exits - to AstraZeneca and Lyell Immunopharma respectively., Raised over $200 million in financings at Arcellx and helped lay the groundwork for its IPO.

## Career timeline

- **AstraZeneca** — Worked in the Corporate Development and Ventures group on M&A, corporate strategy, and portfolio management; led multiple billion-dollar business development deals across 75+ transactions.
- **Arcellx** — Chief Financial Officer; led the company's transition to clinical stage, raised over $200 million in financings, and helped establish the foundation for its IPO.
- **Neogene Therapeutics** — Chief Financial Officer; led financial operations and investor relations and played an instrumental role in the company's acquisition by AstraZeneca.
- **2023** — Appointed President and Chief Financial Officer of ImmPACT Bio (October 31, 2023).
- **2024** — Integral member of the deal team supporting ImmPACT Bio's acquisition by Lyell Immunopharma.
- **2026** — Appointed Co-CEO of Vibrant Therapeutics alongside founder Larry Wang as the company closed $61M in new financing.

## Achievements

- Led or contributed to more than 75 transactions spanning financings, IPO preparations, mergers, acquisitions, and strategic partnerships worth billions in aggregate value.
- Served as CFO of two cell-therapy startups (Neogene and ImmPACT Bio) that both reached successful exits - to AstraZeneca and Lyell Immunopharma respectively.
- Raised over $200 million in financings at Arcellx and helped lay the groundwork for its IPO.
- Holds both a Ph.D. in genetics and an MBA from Yale, bridging deep science and corporate finance.
- Has served as a corporate board member for multiple companies.

## Latest updates

- **2026-01** — Appointed Co-CEO of Vibrant Therapeutics as the company closed $61M in new financing (total raised: $100M) with new investors Pfizer Ventures and Apricot Capital.

## Links

- Website: https://www.vibrantx.com
- LinkedIn: http://www.linkedin.com/in/hanlee80

---

Profile page: https://yespress.io/han-lee
Published by YesPress — https://yespress.io
Last updated: 2026-06-12